Sabby Management’s Altimmune ALT Stock Holding History

Sabby Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-13,800	Closed	-$182K	–	109
2020 Q3	$182K	Buy	+13,800	New	+$276K	0.03%	100
2020 Q1	–	Sell	-44,855	Closed	-$103K	–	89
2019 Q4	$85K	Buy	44,855 +3,097	+7%	+$5.72K	0.02%	64
2019 Q3	$81K	Buy	41,758 +7,553	+22%	+$16.7K	0.04%	76
2019 Q2	$81K	Buy	+34,205	New	+$91.5K	0.1%	72
2019 Q1	–	Sell	-237,921	Closed	-$709K	–	81
2018 Q4	$490K	Buy	+237,921	New	+$842K	0.11%	54

Other funds holding ALT

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sabby Management's ALT Position: Q4 2020 in Review

Sabby Management sold out of Altimmune (ALT) in Q4 2020, closing a stake of 13,800 shares — an estimated $182K sold.

Sabby Management first reported a position in ALT in Q4 2018 and held it in 5 quarters. The position peaked at $490K in Q4 2018. 88 funds tracked by Wall St. Rank hold ALT as of Q4 2020.

Sabby Management reported no remaining Altimmune position as of Q4 2020 after selling out during the quarter.
Sabby Management sold 13,800 Altimmune shares in Q4 2020, an estimated $182K.
Sabby Management first reported a position in Altimmune in Q4 2018 and held it in 5 quarters.
Sabby Management's Altimmune position peaked at $490K in Q4 2018.
88 funds tracked by Wall St. Rank held Altimmune as of Q4 2020.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.